About this trial
Magnesium sulfate is considered a neuroprotective drug and has been studied in various applications. Recently, it has drawn the attention of anesthesiologists, resulting in numerous publications about its role in anesthesiology.
Magnesium sulfate is suggested to exert its neuroprotective effect by preventing excitotoxicity. in the clinical setting, intraoperative magnesium sulfate attenuated POCD. Furthermore, postoperative emergence agitation was significantly reduced in pediatric patients who received intraoperative magnesium sulfate during adenotonsillectomy.
The aim of this study The aim of this work is to compare the protective effect of intraoperative dexmedetomidine with magnesium sulfate against developing POCD and to study their effect on serum level of CRP; the marker of neuronal degeneration.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
ASA physical status I, II and ⅠⅠⅠ
patients undergoing open abdominal surgery under general anesthesia
Disqualifiers
Elderly patients with preoperative MoCA Score below 26.
Operation time more than 4 hours to prevent excessive dosage of magnesium sulfate.
BMI > 35 kg m-2
Trial design
Parallel
Treatments tested in this trial
dexmedetomidine
Drug20 mg/kg as a loading dose over 10 minutes before induction then a maintenance dose of 5 mg/kg/hour, which will also be discontinued at the skin closure.
Treatment groups
Trial outcomes
Primary outcomes
the incidence of Post Operative Cognitive Dysfunction
Post Operative Cognitive Dysfunction
Secondary outcomes
CRP levels and their correlation with POCD
CRP levels and their correlation with POCD
Sponsors and contacts
Click on the lead sponsor to view all of their trials.